HIF1A and prostate cancer: An interesting and specific drug which specifically is targeting HIF-1 and HIF-2 is acriflavine which by binding directly to HIFs can counteract dimerization of HIF-1 and thereby its transcriptional activity [205] has been shown to inhibit growth of prostate cancer and colorectal cancer in preclinical models [206].